Details

Autor(en) / Beteiligte

• Roane, D W
• Harris, M D
• Carpenter, M T
• Finger, D R
• Jarek, M J
• Alloway, J A
• Erickson, A R
• Venanzi, W E
• Drehmer, T J

Titel

Prospective use of intramuscular triamcinolone acetonide in pseudogout

Ist Teil von

• Journal of rheumatology, 1997-06, Vol.24 (6), p.1168

Ort / Verlag

Canada

Erscheinungsjahr

1997

Quelle

MEDLINE

Beschreibungen/Notizen

• To prospectively assess the efficacy of intramuscular (i.m.) triamcinolone acetonide in the treatment of pseudogout. Fourteen patients with crystal proven pseudogout presenting with an acute attack within 5 days of onset were treated with intramuscular triamcinolone acetonide 60 mg and followed for 30 days. Patients with inadequate response were eligible for a 2nd triamcinolone acetonide injection on Day 1-2. Twelve patients had contraindication to nonsteroidal antiinflammatory agents (NSAID). Acute arthritis was monoarticular in 10 patients, and involved 2 or more joints in 4 patients. All patients had good clinical response to triamcinolone acetonide based on restoration of near baseline joint range of motion and joint circumference, and at least 50% improvement in patient and physician global assessment. Major clinical improvement occurred by Day 1-2 (2 patients), Day 3-4 (11 patients), and Day 10-14 (one patient). Six patients required a 2nd triamcinolone acetonide injection on Day 1-2. Toxicities were not observed. I.m. triamcinolone acetonide appears to be safe, well tolerated, and effective in the treatment of pseudogout. It may be a reasonable alternative therapy when NSAID are contraindicated, and for polyarticular attacks where intraarticular corticosteroids are impractical.